| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
23057 |
| Drug |
Talquetamab |
| Brand |
Talvey® |
| Indication |
Talquetamab is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
| Rapid review commissioned |
20/09/2023 |
| Rapid review completed |
10/11/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of talquetamab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
29/11/2023 |
| Pre-submission consultation with Applicant |
23/01/2024 |
| Full submission received from Applicant |
02/05/2024 |
| Preliminary review sent to Applicant |
12/12/2024 |
| NCPE assessment re-commenced |
05/02/2025 |
| Factual accuracy sent to Applicant |
10/04/2025 |
| NCPE assessment re-commenced |
18/04/2025 |
